HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake

Rhea-AI Filing Summary

ALX Oncology Holdings Inc has a Schedule 13G/A amendment reporting that HBM Healthcare Investments (Cayman) Ltd. beneficially owns 8,590,692 shares of common stock, representing approximately 6.5% of the outstanding common stock. The filing states this ownership is calculated using 131,608,278 shares outstanding as of March 2, 2026. Voting and investment power over these shares is exercised by the reporting person’s board of directors, and the amendment is signed by Jean-Marc LeSieur on May 15, 2026.

Insights

Institutional Ownership Analyst

HBM holds a meaningful minority stake of 6.5% in ALX Oncology.

HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 8,590,692 shares, equal to 6.5% of common stock based on 131,608,278 shares outstanding as of March 2, 2026. The stake size is large enough to be visible to investors but below typical control thresholds.

Because voting power is exercised by the reporting person’s board, the position appears managed at the fund level. Subsequent filings could show changes in position size; timing of any disposition or accumulation is not disclosed here.

Corporate Governance Specialist

Ownership is exercised by the reporting entity's board, not by an individual director.

The filing explicitly states that voting and investment power is exercised by the board of HBM Healthcare Investments (Cayman) Ltd., naming six board members. No single board member has individual voting or investment power over the shares according to the comment provided.

This attribution matters for governance signals: votes will follow the board’s collective decisions. Further governance implications depend on any future Schedule 13D/A, proxy disclosures, or voting statements.

Key Figures

Shares beneficially owned: 8,590,692 shares Percent of class: 6.5% Shares outstanding (basis): 131,608,278 shares +2 more

5 metrics

Shares beneficially owned 8,590,692 shares As of <date>March 31, 2026</date>

Percent of class 6.5% Calculated using 131,608,278 shares outstanding as of <date>March 2, 2026</date>

Shares outstanding (basis) 131,608,278 shares As of <date>March 2, 2026</date>

CUSIP 00166B105 Class identifier for Common Stock

Signature date 05/15/2026 Amendment signature by Jean-Marc LeSieur

Key Terms

beneficial owner, Schedule 13G/A, sole voting power, sole dispositive power

4 terms

beneficial owner regulatory

"As of March 31, 2026, the Reporting Person may be deemed the beneficial owner of 8,590,692 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Schedule 13G/A regulatory

"Amendment No. 2 ALX ONCOLOGY HOLDINGS INC Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

sole voting power governance

"Sole Voting Power 8,590,692.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power governance

"Sole Dispositive Power 8,590,692.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What stake does HBM Healthcare hold in ALXO?

HBM Healthcare Investments (Cayman) Ltd. beneficially owns 8,590,692 shares, about 6.5% of ALX Oncology's common stock based on 131,608,278 shares outstanding as of March 2, 2026.

Who controls the voting power for HBM's shares in ALXO?

Voting and investment power over the shares is exercised by the reporting person's board of directors, which the filing lists by name; no individual board member has sole voting or investment power.

As of what date is the ownership percentage calculated?

The approximately 6.5% figure is calculated using 131,608,278 shares outstanding as of March 2, 2026, as stated in the amendment.

When was the Schedule 13G/A signed?

The amendment is signed by Jean-Marc LeSieur, Managing Director, on May 15, 2026, attesting to the reported ownership figures and statements.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ALX ONCOLOGY HOLDINGS INC

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00166B105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00166B105

1

Names of Reporting Persons

HBM Healthcare Investments (Cayman) Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,590,692.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,590,692.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,590,692.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the "Board"). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ALX ONCOLOGY HOLDINGS INC
(b)	Address of issuer's principal executive offices: 323 Allerton Avenue, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: HBM Healthcare Investments (Cayman) Ltd. (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: Governors Square, 23 Lime Tree Bay Avenue, PO Box 30852, Grand Cayman, KY1-1204, Cayman Islands
(c)	Citizenship: Cayman Islands, British West Indies
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 00166B105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of March 31, 2026, the Reporting Person may be deemed the beneficial owner of 8,590,692 shares of Common Stock.
(b)	Percent of class: As of March 31, 2026, the Reporting Person may be deemed the beneficial owner of approximately 6.5% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on 131,608,278 shares of Common Stock outstanding as of March 2, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8,590,692
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8,590,692
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

HBM Healthcare Investments (Cayman) Ltd.

Signature:	/s/ Jean-Marc LeSieur
Name/Title:	Jean-Marc LeSieur, Managing Director
Date:	05/15/2026